Literature DB >> 17425633

Cox regression methods for two-stage randomization designs.

Yuliya Lokhnygina1, Jeffrey D Helterbrand.   

Abstract

Two-stage randomization designs (TSRD) are becoming increasingly common in oncology and AIDS clinical trials as they make more efficient use of study participants to examine therapeutic regimens. In these designs patients are initially randomized to an induction treatment, followed by randomization to a maintenance treatment conditional on their induction response and consent to further study treatment. Broader acceptance of TSRDs in drug development may hinge on the ability to make appropriate intent-to-treat type inference within this design framework as to whether an experimental induction regimen is better than a standard induction regimen when maintenance treatment is fixed. Recently Lunceford, Davidian, and Tsiatis (2002, Biometrics 58, 48-57) introduced an inverse probability weighting based analytical framework for estimating survival distributions and mean restricted survival times, as well as for comparing treatment policies at landmarks in the TSRD setting. In practice Cox regression is widely used and in this article we extend the analytical framework of Lunceford et al. (2002) to derive a consistent estimator for the log hazard in the Cox model and a robust score test to compare treatment policies. Large sample properties of these methods are derived, illustrated via a simulation study, and applied to a TSRD clinical trial.

Entities:  

Mesh:

Year:  2007        PMID: 17425633     DOI: 10.1111/j.1541-0420.2007.00707.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Sample size formulae for two-stage randomized trials with survival outcomes.

Authors:  Zhiguo Li; Susan A Murphy
Journal:  Biometrika       Date:  2011-07-13       Impact factor: 2.445

2.  Pattern-mixture-type Estimation and Testing of Neuroblastoma Treatment Regimes.

Authors:  Xinyu Tang; Abdus S Wahed
Journal:  J Stat Theory Pract       Date:  2015-04

3.  Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.

Authors:  Kelley M Kidwell; Michael A Postow; Katherine S Panageas
Journal:  Clin Cancer Res       Date:  2017-08-23       Impact factor: 12.531

4.  Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials.

Authors:  Zhiguo Li
Journal:  Stat Med       Date:  2016-09-19       Impact factor: 2.373

5.  Cumulative Hazard Ratio Estimation for Treatment Regimes in Sequentially Randomized Clinical Trials.

Authors:  Xinyu Tang; Abdus S Wahed
Journal:  Stat Biosci       Date:  2015-05

6.  Sample size calculations for evaluating treatment policies in multi-stage designs.

Authors:  Ree Dawson; Philip W Lavori
Journal:  Clin Trials       Date:  2010-07-14       Impact factor: 2.486

7.  A global logrank test for adaptive treatment strategies based on observational studies.

Authors:  Zhiguo Li; Marcia Valenstein; Paul Pfeiffer; Dara Ganoczy
Journal:  Stat Med       Date:  2013-09-20       Impact factor: 2.373

8.  SMART designs in cancer research: Past, present, and future.

Authors:  Kelley M Kidwell
Journal:  Clin Trials       Date:  2014-04-14       Impact factor: 2.486

9.  Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised controlled trial.

Authors:  Joseph Donovan; Nguyen Hoan Phu; Nguyen Thi Hoang Mai; Le Tien Dung; Darma Imran; Erlina Burhan; Lam Hong Bao Ngoc; Nguyen Duc Bang; Do Chau Giang; Dang Thi Minh Ha; Jeremy Day; Le Thi Phuong Thao; Nguyen Tt Thuong; Nguyen Nang Vien; Ronald B Geskus; Marcel Wolbers; Raph L Hamers; Reinout van Crevel; Mugi Nursaya; Kartika Maharani; Tran Tinh Hien; Kevin Baird; Nguyen Huu Lan; Evelyne Kestelyn; Nguyen Van Vinh Chau; Guy E Thwaites
Journal:  Wellcome Open Res       Date:  2018-06-20

10.  Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial.

Authors:  Joseph Donovan; Nguyen Hoan Phu; Le Thi Phuong Thao; Nguyen Huu Lan; Nguyen Thi Hoang Mai; Nguyen Thi Mai Trang; Nguyen Thi Thu Hiep; Tran Bao Nhu; Bui Thi Bich Hanh; Vu Thi Phuong Mai; Nguyen Duc Bang; Do Chau Giang; Dang Thi Minh Ha; Jeremy Day; Nguyen Tt Thuong; Nguyen Nang Vien; Ronald B Geskus; Tran Tinh Hien; Evelyne Kestelyn; Marcel Wolbers; Nguyen Van Vinh Chau; Guy E Thwaites
Journal:  Wellcome Open Res       Date:  2018-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.